Company data sheet · Fortrea
Fortrea: three lost years, and the economy wasn't the reason.
- Industry
- Medical Laboratories
- Headquarters
- United States
- Ticker
- FTRE (Nasdaq)
- Sources
- SEC filings (2023–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- October 18, 2026
- From profit to three straight losses. Fortrea earned $0.3 billion in 2021–2022. Then it lost money every year from 2023 to 2025: $1.3 billion in all.
- It wasn't the cycle. The losses began in 2023, a year the US economy grew 2.9%. When a company falls while its economy grows, look inside the company first.
- Still smaller than it was. Revenue reached $2.7 billion in 2025, 11% below its 2021 peak of $3.1 billion.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2021 | $3.1 billion | $0.1 billion | |
| 2022 | $2.8 billion | $0.2 billion | |
| 2023 | $2.8 billion | −$0 billion | |
| 2024 | $2.7 billion | −$0.3 billion | |
| 2025 | $2.7 billion | −$1 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 24 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (16 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 528 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.